Biovitrum Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 400

Employees

  • Latest Deal Type
  • Merger of Eq.

Biovitrum General Information

Description

Provider of pharmaceuticals for common diseases and conditions. The company engages in developing small molecule drugs and recombinant protein therapeutics with focus on metabolic disorders and oncology. The company was spun out of Pharmacia Corporation.

Contact Information

Website
www.biovitrum.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Lindhagensgatan 100
  • 112 76 Stockholm
  • Sweden
Primary Industry
Drug Discovery
Acquirer
Swedish Orphan Biovitrum
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Lindhagensgatan 100
  • 112 76 Stockholm
  • Sweden

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biovitrum Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger of Equals 05-Nov-2009 Completed Generating Revenue
6. PIPE 30-Jun-2009 Completed Generating Revenue
5. Secondary Transaction - Private 27-Mar-2009 Completed Generating Revenue
4. PIPE 30-Sep-2008 Completed Generating Revenue
3. IPO 15-Sep-2006 Completed Generating Revenue
2. Early Stage VC 09-Nov-2001 Completed Startup
1. Buyout/LBO 11-Jun-2001 $130M Completed Startup
To view Biovitrum’s complete valuation and funding history, request access »

Biovitrum Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biovitrum Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
AAC Capital PE/Buyout Minority
Alta Partners Venture Capital Minority
C WorldWide Asset Management Fondsmaeglerselskab Asset Manager Minority
HB Capital Family Office Minority
HBM Partners Venture Capital Minority
You’re viewing 5 of 10 investors. Get the full list »

Biovitrum Acquisitions (2)

Biovitrum’s most recent deal was a Merger/Acquisition with Arexis for . The deal was made on 22-Aug-2005.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Arexis 22-Aug-2005 Merger/Acquisition Drug Discovery
Cambridge Biotechnology 21-Mar-2005 Merger/Acquisition Drug Discovery
To view Biovitrum’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Biovitrum FAQs

  • When was Biovitrum founded?

    Biovitrum was founded in 2001.

  • Where is Biovitrum headquartered?

    Biovitrum is headquartered in Stockholm, Sweden.

  • What is the size of Biovitrum?

    Biovitrum has 400 total employees.

  • What industry is Biovitrum in?

    Biovitrum’s primary industry is Drug Discovery.

  • Is Biovitrum a private or public company?

    Biovitrum is a Private company.

  • What is Biovitrum’s current revenue?

    The current revenue for Biovitrum is .

  • How much funding has Biovitrum raised over time?

    Biovitrum has raised $97.6M.

  • Who are Biovitrum’s investors?

    AAC Capital, Alta Partners, C WorldWide Asset Management Fondsmaeglerselskab, HB Capital, and HBM Partners are 5 of 10 investors who have invested in Biovitrum.

  • When was Biovitrum acquired?

    Biovitrum was acquired on 05-Nov-2009.

  • Who acquired Biovitrum?

    Biovitrum was acquired by Swedish Orphan Biovitrum.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process